Key Developments: Charles River Laboratories International Inc (CRL)
44.90USD
21 May 2013
$-0.01 (-0.02%)
$45.01
$44.96
$45.12
$44.70
128,394
573,108
$46.90
$31.48
Latest Key Developments (Source: Significant Developments)
Charles River Laboratories International Inc Lowers FY 2013 Revenue Guidance; Reaffirms FY 2013 EPS Guidance
Charles River Laboratories International Inc announced that for fiscal 2013, it expects 3% to 5% topline growth and non-GAAP EPS of $2.80 to $2.90. The Company reported revenue of $1.142 billion in fiscal 2012. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $1.175 billion and EPS of $2.85 for fiscal 2013. Full Article
Charles River Laboratories International Inc Reaffirms FY 2013 Guidance-Conference Call
Charles River Laboratories International Inc announced that for fiscal 2013, it expects 4% to 6% topline growth and non-GAAP EPS of $2.80 to $2.90. The Company reported revenue of $1.142 billion in fiscal 2012. According to I/B/E/S Estimates, analysts were expecting the Company to report EPS of $2.86 for fiscal 2013. Full Article
Charles River Laboratories International Inc Reaffirms FY 2013 Guidance
Charles River Laboratories International Inc reaffirmed fiscal 2013 guidance of revenue of 4% to 6% and non-GAAP EPS is $2.80 to $2.90. The Company reported revenue of $1.142 billion in fiscal 2012. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $1.176 billion and EPS of $2.86 for fiscal 2013. Full Article
Charles River Laboratories International Inc Raises FY 2013 Revenue Guidance; Reaffirms FY 2013 EPS Guidance-Conference Call
Charles River Laboratories International Inc announced that fiscal 2013 guidance is now 4% to 6% with the Chinese acquisition of a research model company in China and non-GAAP EPS is $2.80 to $2.90. The Company reported revenue of $1.142 billion in fiscal 2012. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $1.131 billion and EPS of $2.70 for fiscal 2013. Full Article
Charles River Laboratories International Inc Completes Acquisition Of Majority Ownership Of Vital River
Charles River Laboratories International Inc announced that it has completed its acquisition of a 75% ownership of Vital River, the commercial provider of research models and related services in China, and a licensee of Charles River for the last 10 years. As part of the Vital River acquisition, Charles River will be the exclusive global partner for distribution of model creation services offered through Beijing Vital Star Biotechnology. The services of Beijing Vital Star Biotechnology include humanized model creation utilizing inducible pluripotent stem cell (iPS) and other technologies. Charles River acquired the 75% ownership of Vital River for approximately $27 million, subject to certain post-closing working capital adjustments. Full Article
Charles River Laboratories International Inc Comments On FY 2013 Revenue Guidance; Issues FY 2013 EPS Guidance Below Analysts' Estimates; Reaffirms FY 2012 Guidance
Charles River Laboratories International Inc announced that for fiscal 2013, it expects sales growth of 3.0%-5.0%, GAAP EPS of $2.45-$2.55 and Non-GAAP EPS of $2.80-$2.90. The Company reaffirmed fiscal 2012 guidance and expects sales growth of approx. 1%, GAAP EPS of $2.08-$2.13 and Non-GAAP EPS of $2.68-$2.73. The Company reported revenue of $1.142 billion in fiscal 2011. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $1.183 billion for fiscal 2013; EPS of $3.01 for fiscal 2013 and revenue of $1.133 billion for fiscal 2012; EPS of $2.73 for fiscal 2012. Full Article
Charles River Laboratories International Inc Sees FY 2012 Revenue Guidance At Low End Of Prior Range; Raises Low End Of Prior FY 2012 EPS Guidance To A Range In Line With Analysts' Estimates
Charles River Laboratories International, Inc. announced that for fiscal 2012, it expects sales growth of approx. (1)%, GAAP EPS of $2.08-$2.13 and non-GAAP EPS of $2.68-$2.73. The Company reported revenue of $1.143 billion in fiscal 2011. According to I/B/E/S Estimates, analysts are expecting the Company to report EPS of $2.73 on revenues of $1.141 billion for fiscal 2012. Full Article
Charles River Laboratories International Inc Enters Strategic Partnership With Astrazeneca PLC
Charles River Laboratories International Inc announced that it has been selected by Astrazeneca PLC as its preferred strategic partner for outsourced regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics). The three-year agreement extends into 2015. AstraZeneca began the process of transferring programs to Charles River earlier this year. This process is expected to be completed by early 2013. Full Article
Charles River Laboratories International Inc Acquires Accugenix, Inc
Charles River Laboratories International Inc announced that it has acquired Accugenix, Inc., provider of cGMP-compliant contract microbial identification testing, for approximately $17 million in cash. This acquisition strengthens Charles River’s Endotoxin and Microbial Detection1 (EMD) portfolio of products and services by providing clients with microbial detection services for manufacturing in the biopharmaceutical, medical device, nutraceutical and consumer care industries. The acquisition is expected to be neutral to earnings per share on both a GAAP and non-GAAP basis in 2012. In 2013, it is expected to represent approximately 1% of total net sales and be slightly accretive to both GAAP and non-GAAP earnings per share. Full Article
Charles River Laboratories International, Inc. Reaffirms FY 2012 Revenue Guidance; Raises FY 2012 EPS Guidance
Charles River Laboratories International, Inc. announced that for fiscal 2012, it expects sales growth of 1% to 3%, GAAP EPS of $2.12-$2.22 and non-GAAP EPS of $2.63-$2.73. The Company reported revenue of $1.143 billion in fiscal 2011. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
